• Type I DM:
    • SC 0.5-1 unit/kg/day in divided doses
    • Approximately 33-50% of total daily insulin requirement
    • Given with rapid or short-acting insulin
  • Type II DM inadequately controlled on oral medication:
    • SC 10 units/day (or 0.1-0.2 unit/kg/day) in evening or divided BD
  • Type II DM inadequately controlled on GLP-1 receptor agonist:
    • SC 10 units/day given OD in the evening

Pre-filled syringe: 100 units/mL

  • Injected in the stomach area, the thigh or the back of the upper arm
  • Should not be mixed with any other insulin
  • Injection sites should be rotated within the same region from 1 injection to the next to reduce the risk of lipodystrophy

Long-acting insulin

It stimulates peripheral glucose uptake, inhibits hepatic glucose production, inhibits lipolysis and proteolysis regulating glucose metabolism

  • Hypoglycemia
  • Injection site reaction
  • URI
  • Headache
  • Pharyngitis
  • Gastroenteritis
  • Influenza
  • Abdominal pain
  • Back pain
  • Bronchitis
  • Pyrexia
  • Cough
  • Viral infection
  • Nausea
  • Rhinitis
  • Rash
  • Pruritus
  • Vomiting
  • Weight gain
  • Peripheral edema
  • Hypersensitivity reaction
  • Injection site lipodystrophy
  • Hypersensitivity to components
  • IM or IV use
  • Systemic allergic reactions
  • Pramlintide

                          Drug Status

Availability Prescription only
Pregnancy Category B; Can be used
Breastfeeding Can be used
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Levemir 100 IU/mL Injection 5*3mL Novo Nordisk Phillips Therapeutics